Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) issued its earnings results on Wednesday. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46), FiscalAI reports. The business had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $61.92 million. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Fanapt continued strong growth: Second-quarter prescriptions rose 31% year over year and net product sales increased 23% to $36.0 million, supported by the bipolar I disorder launch and an expanded sales force.
• Multiple pipeline and commercial catalysts are approaching: BYSANTI is expected to launch in the second half of 2026, Quimilza has a December 2026 FDA action date, and late-stage readouts for NEREUS, VQW-765, and HETLIOZ are expected by year-end.
• Profitability and cash usage deteriorated: Second-quarter net loss widened to $62.5 million from $27.2 million a year earlier, while operating expenses rose 25% to $114.3 million; management expects 2026 cash burn to exceed 2025 levels.
• HETLIOZ sales remain pressured by generic competition: Second-quarter revenue fell 66% to $5.6 million, although approximately $7 million of shipments delayed until July will be recognized in the third quarter.
• NEREUS launch results remain difficult to assess: The product generated $1.0 million in recognized sales, while $12.6 million of wholesaler-related revenue was constrained because of uncertainty around patient demand and potential returns from elevated inventory levels.

Vanda Pharmaceuticals Price Performance

VNDA traded down $0.24 on Wednesday, hitting $5.09. 1,592,959 shares of the company were exchanged, compared to its average volume of 1,682,651. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.15 and a current ratio of 2.16. The business’s fifty day moving average is $5.87 and its 200 day moving average is $6.80. Vanda Pharmaceuticals has a fifty-two week low of $4.14 and a fifty-two week high of $9.94. The firm has a market capitalization of $306.06 million, a P/E ratio of -1.26 and a beta of 0.64.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares in the last quarter. Quarry LP purchased a new position in Vanda Pharmaceuticals in the 3rd quarter valued at approximately $53,000. Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals during the second quarter worth $69,000. Boothbay Fund Management LLC acquired a new position in Vanda Pharmaceuticals during the third quarter worth $72,000. Finally, Engineers Gate Manager LP purchased a new stake in Vanda Pharmaceuticals during the second quarter worth $75,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on VNDA shares. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.30.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.